Can dupixent be used for nasal polyps?

Can dupixent help nasal polyps?

Dupixent is approved to treat chronic rhinosinusitis with nasal polyps in adults and adolescents 12 years and older. It reduces polyp size and improves nasal blockage by blocking interleukin-4 and interleukin-13 signaling.

How long does it take to see results?

Most patients notice reduced nasal congestion within a few weeks, while polyp shrinkage can take 8 to 16 weeks. Full benefit may require up to 24 weeks of treatment.

What happens when treatment stops?

Nasal polyp symptoms and polyp size often return after stopping Dupixent, sometimes within months. Continuous therapy is usually needed to maintain control.

Are there side effects patients worry about?

Common concerns include injection-site reactions, conjunctivitis, and joint pain. Eosinophilic pneumonia and parasitic infections are rare but reported.

Who makes Dupixent and when does its patent expire?

Regeneron and Sanofi produce Dupixent. The primary U.S. composition-of-matter patent expires in 2027, although secondary patents may extend exclusivity into the early 2030s.

Can biosimilars reach the market before patent expiry?

Biosimilar developers have filed patent challenges, but regulatory approval and launch timing remain uncertain until the courts and FDA resolve ongoing litigation.

How does Dupixent compare with other nasal polyp treatments?

Unlike nasal corticosteroid sprays or surgery, Dupixent targets the underlying type 2 inflammation rather than just local symptoms. It is usually reserved for patients whose polyps persist despite steroids or prior surgery.

[1] https://www.drugpatentwatch.com/drug/dupixent